Deals In Depth: December 2014
Pfizer received worldwide rights to Opko Health's Phase III human growth hormone Lagova; Merck and Otsuka made billion-dollar M&As in infectious and neurological diseases, respectively. Biopharma and device financing were down compared with November.
You may also be interested in...
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.